HIF1A and pulmonary arterial hypertension: Conceivably, HIF-1α inhibitors are also potential therapeutic agents for HIF-1α-mediated diseases—including pulmonary arterial hypertension, hereditary erythrocytosis, obstructive sleep apnea, ocular neovascularization and traumatic shock19, 20—as well as Th17-mediated inflammatory diseases.